Completed PHASE2 NCT00065351

Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

A Multicenter, Open-label Study to Determine the Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

Sponsor: Celgene

Conditions Multiple Myeloma

Interventions CC-5013

Updated 7 times since 2017 Last updated: Nov 7, 2019 Started: Jul 1, 2003 Primary completion: Oct 1, 2006 Completion: Mar 1, 2007

Listed as NCT00065351, this PHASE2 trial focuses on Multiple Myeloma and remains completed. Sponsored by Celgene, it has been updated 7 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Dec 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Dec 2019 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene

Data source: Celgene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Berkeley, United States , Bethesda, United States , Boston, United States , Brooklyn, United States , Burbank, United States , Charlotte, United States , Chicago, United States , Cleveland, United States , Glendale, United States and 14 more locations